Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
Open Access
- 21 April 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (5)
- https://doi.org/10.1128/aac.01923-19
Abstract
In children requiring lopinavir coformulated with ritonavir in a 4:1 ratio (lopinavir-ritonavir-4:1) and rifampin, adding ritonavir to achieve a 4:4 ratio with lopinavir (LPV/r-4:4) overcomes the drug-drug interaction. Possible drug-drug interactions within this regimen may affect abacavir concentrations, but this has never been studied. Children weighing <15 kg needing rifampin and LPV/r-4:4 were enrolled in a pharmacokinetic study and underwent intensive pharmacokinetic sampling on 3 visits: (i) during the intensive and (ii) continuation phases of antituberculosis treatment with LPV/r-4:4 and (iii) 1 month after antituberculosis treatment completion on LPV/r-4:1. Pharmacometric modeling and simulation were used to compare exposures across weight bands with adult target exposures. Eighty-seven children with a median (interquartile range) age and weight of 19 (4 to 64) months and 8.7 (3.9 to 14.9) kg, respectively, were included in the abacavir analysis. Abacavir pharmacokinetics were best described by a two-compartment model with first-order elimination and transit compartment absorption. After allometric scaling adjusted for the effect of body size, maturation could be identified: clearance was predicted to be fully mature at about 2 years of age and to reach half of this mature value at about 2 months of age. Abacavir bioavailability decreased 36% during treatment with rifampin and LPV/r-4:4 but remained within the median adult recommended exposure, except for children in the 3- to 4.9-kg weight band, in which the exposures were higher. The observed predose morning trough concentrations were higher than the evening values. Though abacavir exposure significantly decreased during concomitant administration of rifampin and LPV/r-4:4, it remained within acceptable ranges. (This study is registered in ClinicalTrials.gov under identifier NCT02348177.)Funding Information
- Drugs for Neglected Diseases initiative
- National Research Foundation
- Wellcome Trust (206379/Z/17/Z)
This publication has 40 references indexed in Scilit:
- Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and XposeCPT: Pharmacometrics & Systems Pharmacology, 2013
- Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected ChildrenThe New England Journal of Medicine, 2012
- Low Incidence of Abacavir Hypersensitivity Reaction Among African Children Initiating Antiretroviral TherapyThe Pediatric Infectious Disease Journal, 2011
- Cytochrome P450 3A4 mRNA Is a More Reliable Marker than CYP3A4 Activity for Detecting Pregnane X Receptor-Activated Induction of Drug-Metabolizing EnzymesDrug Metabolism and Disposition, 2010
- Steady-State Pharmacokinetics of Abacavir in Plasma and Intracellular Carbovir Triphosphate following Administration of Abacavir at 600 Milligrams Once Daily and 300 Milligrams Twice Daily in Human Immunodeficiency Virus-Infected SubjectsAntimicrobial Agents and Chemotherapy, 2009
- A Review of the Pharmacokinetics of AbacavirClinical Pharmacokinetics, 2008
- Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV‐infected patients on HAARTBritish Journal of Clinical Pharmacology, 2005
- Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patientsBritish Journal of Clinical Pharmacology, 2005
- Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell lineJournal of Pharmaceutical Sciences, 2001
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000